September 2012

Targeted therapies, personalized medicine, and best management approaches will be the central topics of discussion at the 7th New York Lung Cancer Symposium.

A thorough examination of emerging strategies for the treatment of breast cancer, as well as the clinical data underlying new and existing options, will form the cornerstone of the 9th Annual School of Breast Oncology.

The expansion of testing for genetic abnormalities in patients with advanced lung cancer is generating questions about which patients' tumors should be tested, how they should be tested, and whether they should be retested.

Many researchers and oncologists anticipate a role for antiangiogenic strategies in future treatment paradigms; yet just what that role will be remains elusive.

An interview with Elaine R. Mardis, PhD, discussing the clinical applications of genomic research on the near horizon that will enable more personalized therapy for patients at earlier stages of breast cancer.

The heterogeneity of lung tumors generates challenges in terms of the costs and logistics of developing targeted therapies, given that relatively few patients may harbor a particular mutation.

Within the past two years, the oncology community has seen the FDA approve three practice-changing therapies for breast cancer and the progress of a promising fourth agent, T-DM1.

Jeffrey S. Weber, MD, PhD, specializes in cancer immunotherapy and has been involved in numerous trials of clinical drug development, vaccines, and studies on autoimmunity and melanoma.

Though located far downstream of the extracellular trigger that initiates its signaling pathway, the MEK protein is no less significant a player in the cascade of events that promotes key cellular processes.

As Bonnie Addario has gone from patient to survivor, she has learned much about what patients are looking for in terms of information and care.

Combining tamoxifen with everolimus increased the clinical benefit rate, time to progression, and overall survival versus tamoxifen alone in postmenopausal women with metastatic breast cancer.

Concurrent mutations in MEK1 and BRAF genes do not confer resistance to BRAF inhibitors in advanced melanoma, contrary to what investigators had expected.

A study evaluating first-line chemotherapy dosing strategies for treating patients with advanced epithelial ovarian cancer has delivered practice-changing findings.

Trastuzumab has demonstrated activity in patients with B-cell adult acute lymphocytic leukemia who exhibit evidence of upregulation of the HER2 receptor.